ADMA Biologics, Inc. ADMA

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year 2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year 2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year 2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Yea

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report second quarter 2026 financial results on August 5, 2026, after the U.S. financial markets close. ADMA’s management team will host a li

In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day.